RNA interference-mediated validation of survivin and Apollon/BRUCE as new therapeutic targets for cancer therapy

Marzia Pennati, Enrico Millo, Paolo Gandellini, Marco Folini, Nadia Zaffaroni

Research output: Contribution to journalArticlepeer-review


The ability to evade apoptosis is one of the defining hallmarks of cancer. It enables the survival of cancer cells under abnormal growth stimulation and mediates their increased resistance to treatment with cytotoxic drugs and radiation. Therefore, antiapoptotic proteins that counteract apoptosis signaling represent promising new therapeutic targets to impair cancer cell growth and enhance treatment response. As soon as RNA interference (RNAi) was demonstrated in mammalian cells, it rapidly became an essential tool for gene knockdown in preclinical models, making it possible to define the role of specific genes in the onset and progression of cancer and explore their potential as therapeutic targets. The present review summarizes the findings from studies relying on the use of RNAi-based approaches to functionally validate two members of the inhibitors of apoptosis protein family, survivin and Apollon/BRUCE, as new cancer therapeutic targets. Results collected thus far indicate that targeting the survivin network efficiently inhibits tumor growth potential and increases spontaneous and treatment-induced apoptosis of cancer cells. Based on these findings, the applicability of survivin-directed strategies for the clinical treatment of human tumors is currently under investigation. As regards Apollon/ BRUCE, although very preliminary, results of RNAi-mediated gene knockdown point to the possibility to significantly impair tumor cell proliferation through the induction of apoptosis.

Original languageEnglish
Pages (from-to)69-78
Number of pages10
JournalCurrent Topics in Medicinal Chemistry
Issue number2
Publication statusPublished - Jan 2012


  • Apollon/BRUCE
  • Apoptosis
  • Chemosensitivity
  • Human tumors
  • Inhibitors of apoptosis proteins
  • Radiosensitivity
  • Survivin

ASJC Scopus subject areas

  • Drug Discovery


Dive into the research topics of 'RNA interference-mediated validation of survivin and Apollon/BRUCE as new therapeutic targets for cancer therapy'. Together they form a unique fingerprint.

Cite this